BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

A friendly reminder that the main Hyperthermia conference events in the US, Europe and ASIA, (STM, ESHO, ACHO) are right around the corner. These conferences are a gathering of the best in hyperthermia research and an excellent resource for those interested in the field of thermal oncology.

The 35th Annual Meeting of the Society for Thermal Medicine, 32nd Annual Meeting of the European Society for Hyperthermic Oncology and 7th Annual Asia Conference of Hyperthermic Oncology will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding of thermal medicine in the context of engineering, physics, materials science, and biology.

Keynote and Plenary speakers will highlight the extensive connections between physics, information science, biology, imaging, and the thermal state.

STM ESHO ACHO 2018

Who Should Attend?

  • Researchers in the field of thermal oncology
  • Clinicians, new to the field, who would like to talk with experts
  • Clinicians who want to expand their thermal oncology program
  • Medical Students that want to understand how hyperthermia may impact the future of medicine.
  • Pyrexar Distributors who want to expand their working knowledge of hyperthermia
  • Potential purchasers of hyperthermia equipment

Here are some dates to help you plan

  STM ESHO ACHO
Conference Dates: May 7-10 May 16-19 May 23-25
Location: Tuscon, Arizona Berlin, Germany Seoul, Korea
Venue: Westin La Paloma Resort Langenbeck-Virsho Hause The Catholic University
of Korea
Conference Pass: $650 - $1300 € 350 - €500 $235 USD
Hotel: $109 €149 - €218  
Show Website:

Hope to see you there!

A friendly reminder that the main Hyperthermia Conference Events in the US and Europe are right around the corner. These conferences are a gathering of the best in hyperthermia research and an excellent resource for those interested in the field of thermal oncology.

STM ESHO 2019

The 36th Annual Meeting of the Society for Thermal Medicine and the 33rd Annual Meeting of the European Society for Hyperthermic Oncology will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding of thermal medicine in the context of engineering, physics, materials science, and biology.

Keynote and Plenary speakers will highlight the extensive connections between physics, information science, biology, imaging, and the thermal state.

New: Clinical Hyperthermia Training Added to STM

  • How to establish a hyperthermia program
  • Practice guidelines for superficial hyperthermia
  • Practice guidelines for deep hyperthermia
  • Practice guidelines for interstitial hyperthermia
  • Equipment, planning, and execution of MW superficial hyperthermia treatment
  • Equipment, planning, and execution of RF deep hyperthermia treatment
  • Assessment of hyperthermia treatments based on hypoxia imaging
  • Clinical workflow, documentation and reimbursement of hyperthermia treatments
  • Impact of hyperthermia referrals in a Radiation Oncology Department

Who Should Attend?

  • Researchers in the field of thermal oncology
  • Clinicians, new to the field, who would like to talk with experts
  • Clinicians who want to expand their thermal oncology program
  • Medical Students that want to understand how hyperthermia may impact the future of medicine.
  • Pyrexar Distributors who want to expand their working knowledge of hyperthermia
  • Potential purchasers of hyperthermia equipment

Here are some dates to help you plan

  STM ESHO
Conference Dates: Apr 28 - May 2 May 22-24
Location: St. Pete's Beach, Florida Warsaw, Poland
Venue: Tradewinds Grand Island Resort Warsaw Plaza Hotel
Conference Pass: $650 - $1300 € 250 - €400
Hyperthermia Workshop/Training $75 € 35 - €65
Hotel: $255 - $345 €149 - €218
Show Website:

 

A few facts that I learned during my visit to Kuwait; 1) gas is fifth cheapest in the world 2) the temperature can get hot enough to melt your tires and 3) the region has excellent healthcare resources.

A local distributor, MedVision, is looking to bring hyperthermia to Kuwait and the surrounding region. MedVision, a division of SADITA Holdings Group, is considered one of the fast growing companies in this field. Established in 2010 they are considered the market leaders in the territory, representing well known companies in the cardiology, cardiac surgery and peripheral intervention.

Physicians gathered at the Kuwait Cancer Center to learn about advancements in hyperthermia.  In addition to Mark Falkowski's Pyrexar's product overview presentation, MedVision invited hyperthermia expert and Director of the division of Translational Radiation Sciences at the University of Maryland School of Medicine, Dr. Zeljko Vujaskovic.

Ali Rabie, Senior Product Specialist, MedVision | Mark Falkowski, CEO - Pyrexar Medical | Ahmed El Ghamry, Business Unit Manager, MedVision

MedVision Headquarters, Safat, Kuwait

Dr. Zeljko Vujaskovic., Director of Translational Radiation Sciences at the University of Maryland School of Medicine

Oncologist gather at Kuwait Cancer Center to hear how hyperthermia can assist them in the treatment of cancer

previous arrownext arrow
Slider

Dr. Vujaskovic has published more than 150 articles and book chapters on radiation therapy, radiation injury, and hyperthermia topics. He has directed national and international research collaborations and is an active participant in cooperative group trials. He maintains an active clinical practice, with a focus on advanced treatment approaches in prostate cancer. His presentation “Principles of Hyperthermia in Cancer Treatment” was well received. "The more we can get oncologist engaged, the greater the chance hyperthermia will return to its place as a pillar of cancer treatment"

We are in negotiations with MedVision to become an authorized distributor for Kuwait with expansion into Qatar, Bahrain, Saudi Arabia, Lebanon, Jordan, Egypt, UAE, Oman, Iraq & Iran.

ORR 2018

A reminder that he ORR (Oncoradiology, Radiology and Radiotherapy) Congress will be held in Moscow, Russia at the Holiday Inn from February 16-17, 2018. Representing Pyrexar Medical's hyperthermia product line will be our distributor Sennewald Medizintechnik, GmbH.

screenshot oncoradiology.ru 2017 12 11 11 49 01The main goal of the conference is to provide a platform for radiodiagnosticians, radiotherapists and medical physicists for education, ideas and experience exchange, discussion of actual issues and professional communication. For the first time ever traditional conferences such as “Radiodiagnosis Standards in Oncology”, “Radiotherapy in Oncology”, “Medical Physics in Oncology”, “Interventional Radiology in Oncology”, “Radionuclide Therapy in Oncology” and the conference with international participation “PET in Oncology” will be considered within the same event. In addition, for the first time the conference “Ultrasonic Diagnosis in Oncology”, dedicated to the memory of Professor S. Balter will be performed and discussion site for fundamental and theoretical problems in radiobiology will be provided.

A link to registration can be found here.

I just returned from a five day trip to India at the invitation of our distributor Kirloskar Technologies (KTPL). A special thanks to the planning and support of Mr. Ketan Desai, President of the Oncology Business at KTPL, for arranging the site visits and taking such good care of us. India is a very large market and can play an important role for growth of Pyrexar. To put the Indian market into perspective, the country represents just under 18% of the world population (1.34 billion population) packed into a land mass 1/3 the size of the US (323 million people). Treating the nation's cancer patients is a serious challenge.

Sasi Sekhar, KTPL Service Manager | Ketan Desai, President Oncology Business, KTPL | Dr. Geeta S Narayanan, Vydehi Institute | Mark Falkowski, CEO, Pyrexar Medical | Dr. Lokesh Viswanath | Dr. R. Vinaykumar

Mr. Sayan Bhattacharya | Dr. Jigna Bhattacharya, Assoc. Professor, Gujarat Cancer & Research Institute | Mark Falkowski, CEO, Pyrexar Medical | Ketan Desai, President Oncology Business, KTPL

Mark Falkowski, CEO, Pyrexar Medical | Dr. Nagraj Huilgol, Chief Radiation Oncologist, Nanavati Super Specialty Hospital | Ketan Desai, President Oncology Business, KTPL

Dr. Huilgol currently practicing at Nanavati. "Don't let the quaint exterior fool you, this is as modern a facility as any I have visited in the US" says Mark Falkowski

previous arrow
next arrow
previous arrownext arrow
Slider


The journey took us down the western coast of India where we visited with several key hospitals targeted to introduce our radiative hyperthermia product line to the country. From Ahmedabad in the Northwestern state of Gujarat, to the coastal city of Mumbai in Maharashtra, to the southern city of Bangalore in Karnataka.  Information was well received, but they all asked the same question "Where have you been". That question is a little difficult to answer as our products are well established in European nations, in the US , China and growing rapidly on the Korean peninsula.

Where have you been? Why isn't Pyrexar in India?

Pyrexar has seen tremendous growth in the last three years. The regulatory requirements to enter each new country are rigorous and we have been working quickly to bring proven hyperthermia treatment to the world. As we start filling the void, lesser technologies are pushed aside and replaced. The plain truth to why we are not active in India is that we did not have solid distribution partners, until now. Kirloskar Technologies has the technical understanding, product depth and reach, and a service team that can handle our product line. With this partnership in place, it is possible to bring our systems to market in India.

One of the highlights of the trip was my meeting with Dr. Nagraj Huilgol. As you may know, Dr. Huilgol is a hyperthermia advocate and researcher with more than 100 publications in national and international journals. He was lead researcher in a phase III clinical study on head and neck cancer using capacitive hyperthermia. His CV includes Chief Editor of the Journal of Cancer Research and Therapeutics (JCRT) and a member of editorial boards of the Indian Journal of Cancer, Indian Journal of Head and Neck Cancer, International Journal of Hyperthermia and official journal of ASHO, ESHO and NAHO. Having this well known hyperthermia expert as a luminary will help usher hyperthermia into India.